These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 38763873

  • 1. [Investigation on the treatment of empagliflozin in glycogen storage disease type Ⅰb].
    Jiang JJ, Ma MS, Wei M, Qiu ZQ.
    Zhonghua Er Ke Za Zhi; 2024 Jun 02; 62(6):526-529. PubMed ID: 38763873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Short-term efficacy of empagliflozin in children with glycogen storage disease type Ⅰb].
    Jiang JJ, Zheng X, Ma MS, Cui XG, Jian S, Tang XY, Bao XD, Zhang SM, Ma JR, Song HM, Qiu ZQ.
    Zhonghua Er Ke Za Zhi; 2023 Jun 02; 61(6):515-519. PubMed ID: 37312462
    [Abstract] [Full Text] [Related]

  • 7. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
    Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M.
    Blood; 2020 Aug 27; 136(9):1033-1043. PubMed ID: 32294159
    [Abstract] [Full Text] [Related]

  • 8. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
    Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ, Zhou ZZ, Zeng CH, Tao CY, Liu ZC, Zhang W, Liu L.
    Orphanet J Rare Dis; 2024 Apr 11; 19(1):155. PubMed ID: 38605407
    [Abstract] [Full Text] [Related]

  • 9. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
    Grünert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P, Jones N, Uçar SK, LaFreniere J, Contreras EL, Pendyal S, Rossi A, Schneider B, Spiegel R, Stepien KM, Wesol-Kucharska D, Veiga-da-Cunha M, Wortmann SB.
    Mol Genet Metab; 2024 Mar 11; 141(3):108144. PubMed ID: 38277989
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.
    Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y, Ma N, Lan J, Zhang Y, Niu H, Shang L, Jiang X, Yang M.
    Sci Rep; 2024 Apr 15; 14(1):8630. PubMed ID: 38622211
    [Abstract] [Full Text] [Related]

  • 12. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
    Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR.
    Orphanet J Rare Dis; 2022 May 12; 17(1):195. PubMed ID: 35549996
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M.
    Lancet Diabetes Endocrinol; 2021 Feb 12; 9(2):106-116. PubMed ID: 33357505
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
    Boulanger C, Stephenne X, Diederich J, Mounkoro P, Chevalier N, Ferster A, Van Schaftingen E, Veiga-da-Cunha M.
    J Inherit Metab Dis; 2022 Jul 12; 45(4):759-768. PubMed ID: 35506446
    [Abstract] [Full Text] [Related]

  • 19. Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation.
    Küçükçongar Yavaş A, Engin Erdal A, Bilginer Gürbüz B, Ünlüsoy Aksu A, Kasapkara ÇS.
    J Pediatr Endocrinol Metab; 2023 Nov 27; 36(11):1092-1099. PubMed ID: 37791580
    [Abstract] [Full Text] [Related]

  • 20. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
    Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, Widmer A, Urwyler SA, Ebrahimi F, Vogt DR, Winzeler B, Christ-Crain M.
    J Am Soc Nephrol; 2020 Mar 27; 31(3):615-624. PubMed ID: 32019783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.